These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 25227815)

  • 21. Clinico-pathological pattern of extranodal non-Hodgkin's lymphoma in Saudi Arabia.
    Al Diab AR; Aleem A; Qayum A; Al Askar AS; Ajarim DS
    Asian Pac J Cancer Prev; 2011; 12(12):3277-82. PubMed ID: 22471466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C; Li W; Liu C; He H; Bai O
    Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma glutathione S-Transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV).
    Katahira T; Takayama T; Miyanishi K; Hayashi T; Ikeda T; Takahashi Y; Takimoto R; Matsunaga T; Kato J; Niitsu Y
    Clin Cancer Res; 2004 Dec; 10(23):7934-40. PubMed ID: 15585627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of the international prognostic index in a study of Chinese patients with non-Hodgkin's lymphoma and a high incidence of primary extranodal lymphoma.
    Mok TS; Steinberg J; Chan AT; Yeo WM; Hui P; Leung TW; Johnson P
    Cancer; 1998 Jun; 82(12):2439-48. PubMed ID: 9635538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary gastrointestinal non-Hodgkin's lymphoma: treatment outcome.
    Al-Shemmari SH; Sajnani KP; Ameen RM; Ragheb AM
    Clin Lymphoma; 2003 Sep; 4(2):99-103. PubMed ID: 14556681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prognostic factors of invasive non-Hodgkin's lymphoma].
    Yu H; Hong XN; Li J; Peng LP; Ye L
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):461-3. PubMed ID: 17974284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era.
    Gutiérrez-García G; Colomo L; Villamor N; Arenillas L; Martínez A; Cardesa T; García-Herrera A; Setoain X; Rodríguez S; Ghita G; Abrisqueta P; Giné E; Bosch F; Campo E; Montserrat E; López-Guillermo A
    Leuk Lymphoma; 2010 Jul; 51(7):1225-32. PubMed ID: 20497002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL).
    Lombardo M; Morabito F; Merli F; Molica S; Cavanna L; Sacchi S; Broglia C; Angrilli F; Ilariucci F; Stelitano C; Luisi D; Bertè R; Luminari S; Federico M; Brugiatelli M;
    Leuk Lymphoma; 2002 Sep; 43(9):1795-801. PubMed ID: 12685834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
    Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A
    N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical features and prognosis of mucosa-associated lymphoid tissue lymphoma: a report of 90 cases].
    Zhai LZ; Xiao J; Fu XH; Ye S; Guo CC; Huang JJ; Tian Y; Lin HL; Lin TY
    Ai Zheng; 2009 Jul; 28(7):734-9. PubMed ID: 19624901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients.
    Zhang T; Wu Y; Ju H; Meng J; Guo W; Ren G
    Cancer Med; 2020 Jan; 9(1):194-203. PubMed ID: 31733094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
    Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
    Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Head and neck extra nodal NHL (HNENL)--Treatment Outcome and Pattern of failure--A Single Institution Experience.
    Giridhar P; Mallick S; Bhasker S; Pathy S; Mohanti BK; Biswas A; Sharma A
    Asian Pac J Cancer Prev; 2015; 16(15):6267-72. PubMed ID: 26434827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis.
    Gómez H; Hidalgo M; Casanova L; Colomer R; Pen DL; Otero J; Rodríguez W; Carracedo C; Cortés-Funes H; Vallejos C
    J Clin Oncol; 1998 Jun; 16(6):2065-9. PubMed ID: 9626205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Localized extranodal lymphoma of the head and neck: retrospective analysis of a series of 107 patients from a single institution.
    Frata P; Buglione M; Grisanti S; Bonetti B; Vitali E; De Stefani A; Magri E; Peveri A; Marini G; Rossi G; Magrini SM
    Tumori; 2005; 91(6):456-62. PubMed ID: 16457141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Survival of patients with aggressive non-hodgkin's lymphoma: no difference between first line treatment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice].
    van Agthoven M; Wittebol S; Budel LM; Uyl-de Groot CA; Kramer MH
    Ned Tijdschr Geneeskd; 2004 Jan; 148(2):88-93. PubMed ID: 14753131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG).
    Papaxoinis G; Papageorgiou S; Rontogianni D; Kaloutsi V; Fountzilas G; Pavlidis N; Dimopoulos M; Tsatalas C; Xiros N; Economopoulos T
    Leuk Lymphoma; 2006 Oct; 47(10):2140-6. PubMed ID: 17071488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Localized non-Hodgkin's lymphoma of Waldeyer's ring: clinical features, management, and prognosis of 130 adult patients.
    Ezzat AA; Ibrahim EM; El Weshi AN; Khafaga YM; AlJurf M; Martin JM; Ajarim DS; Bazarbashi SN; Stuart RK; Zucca E
    Head Neck; 2001 Jul; 23(7):547-58. PubMed ID: 11400243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.